Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Don’t Cause Disruptions in Drug Distribution with October Re-Pricing: Japan Wholesaler Chief
January 15, 2019
- Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief
January 9, 2019
- Generic Use Rate at 73.2% in July-September: JGA
December 27, 2018
- JMA Chief Pushes September 2019 Drug Price Announcement for Ad-Hoc Revision
December 27, 2018
- Use of Generics and Formulary Would Reduce Drug Expenditure by 38%: Payer Estimate
December 27, 2018
- March Announcement of NHI Price List “Not an Option”, Says Wholesaler Group
December 25, 2018
- October 2019 Drug Price Revision a Relief for JPMA: Official
December 25, 2018
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
- Lilly’s Jonsson to Stay as PhRMA Japan Chief
December 13, 2018
- 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018
- JPMA Chief Warns against Japan Govt’s Short-Sighted Budgeting, Calls for Longer-Term View on Innovation
November 26, 2018
- 8 Infectious Disease-Related Societies Launch New Organization to Combat Drug-Resistance Problem
November 12, 2018
- 7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey
November 9, 2018
- Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns
November 6, 2018
- Japan, US, Europe Trade Groups Stress Importance of Drug Discovery, Call for “Angel Cycle”
November 5, 2018
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
- EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman
October 16, 2018
- Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
October 15, 2018
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…